Which has higher valuation and earnings, GKOS or RMD?

ResMed has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 20.71 -$187.69M -$3.25 N/A ResMed $5.65B 5.82 $1.52B $10.43 21.88

Is GKOS or RMD more profitable?

ResMed has a net margin of 26.94% compared to Glaukos' net margin of -30.68%. ResMed's return on equity of 25.58% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -30.68% -6.37% -4.78% ResMed 26.94% 25.58% 18.89%

Does the media refer more to GKOS or RMD?

In the previous week, ResMed had 15 more articles in the media than Glaukos. MarketBeat recorded 19 mentions for ResMed and 4 mentions for Glaukos. Glaukos' average media sentiment score of 1.67 beat ResMed's score of 1.25 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ResMed 15 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, GKOS or DXCM?

DexCom has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 20.71 -$187.69M -$3.25 N/A DexCom $4.66B 7.11 $836.30M $2.53 34.74

Is GKOS or DXCM more profitable?

DexCom has a net margin of 20.12% compared to Glaukos' net margin of -30.68%. DexCom's return on equity of 35.94% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -30.68% -6.37% -4.78% DexCom 20.12% 35.94% 14.75%

Does the media favor GKOS or DXCM?

In the previous week, DexCom had 9 more articles in the media than Glaukos. MarketBeat recorded 13 mentions for DexCom and 4 mentions for Glaukos. Glaukos' average media sentiment score of 1.67 beat DexCom's score of 1.19 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive DexCom 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GKOS or GEHC?

In the previous week, GE HealthCare Technologies had 7 more articles in the media than Glaukos. MarketBeat recorded 11 mentions for GE HealthCare Technologies and 4 mentions for Glaukos. Glaukos' average media sentiment score of 1.67 beat GE HealthCare Technologies' score of 1.17 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive GE HealthCare Technologies 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PHG or GKOS?

Glaukos has a consensus price target of $178.08, suggesting a potential downside of 0.07%. Given Glaukos' stronger consensus rating and higher possible upside, analysts plainly believe Glaukos is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Koninklijke Philips 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Glaukos 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.79

Which has stronger valuation & earnings, PHG or GKOS?

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Koninklijke Philips $20.17B 1.26 $1.01B $1.36 19.04 Glaukos $507.44M 20.71 -$187.69M -$3.25 N/A

Does the media refer more to PHG or GKOS?

In the previous week, Glaukos had 1 more articles in the media than Koninklijke Philips. MarketBeat recorded 4 mentions for Glaukos and 3 mentions for Koninklijke Philips. Glaukos' average media sentiment score of 1.67 beat Koninklijke Philips' score of 0.52 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Koninklijke Philips 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings and valuation, GKOS or STE?

STERIS has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 20.71 -$187.69M -$3.25 N/A STERIS $5.94B 3.69 $782.30M $8.18 27.46

Is GKOS or STE more profitable?

STERIS has a net margin of 13.34% compared to Glaukos' net margin of -30.68%. STERIS's return on equity of 14.34% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -30.68% -6.37% -4.78% STERIS 13.34% 14.34% 9.66%

Does the media prefer GKOS or STE?

In the previous week, Glaukos and Glaukos both had 4 articles in the media. Glaukos' average media sentiment score of 1.67 beat STERIS's score of 0.99 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive STERIS 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Glaukos (GKOS) Competitors

$178.20 +0.73 (+0.41%)

As of 09/4/2026 03:58 PM Eastern

Compare

GKOS vs. RMD, DXCM, GEHC, PHG, and STE

Should you buy Glaukos stock or one of its competitors? Glaukos's main competitors and comparable companies include ResMed (RMD), DexCom (DXCM), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), and STERIS (STE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Glaukos compare to ResMed?

Glaukos (NYSE:GKOS) and ResMed (NYSE:RMD) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Glaukos presently has a consensus target price of $178.08, suggesting a potential downside of 0.07%. ResMed has a consensus target price of $240.31, suggesting a potential upside of 5.28%. Given ResMed's higher probable upside, analysts clearly believe ResMed is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
ResMed	0 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

99.0% of Glaukos shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 5.9% of Glaukos shares are held by insiders. Comparatively, 0.7% of ResMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, ResMed had 15 more articles in the media than Glaukos. MarketBeat recorded 19 mentions for ResMed and 4 mentions for Glaukos. Glaukos' average media sentiment score of 1.67 beat ResMed's score of 1.25 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ResMed	15 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ResMed has a net margin of 26.94% compared to Glaukos' net margin of -30.68%. ResMed's return on equity of 25.58% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
ResMed	26.94%	25.58%	18.89%

Glaukos has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, ResMed has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

ResMed has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	20.71	-$187.69M	-$3.25	N/A
ResMed	$5.65B	5.82	$1.52B	$10.43	21.88

Summary

ResMed beats Glaukos on 10 of the 16 factors compared between the two stocks.

How does Glaukos compare to DexCom?

Glaukos (NYSE:GKOS) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

DexCom has a net margin of 20.12% compared to Glaukos' net margin of -30.68%. DexCom's return on equity of 35.94% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
DexCom	20.12%	35.94%	14.75%

In the previous week, DexCom had 9 more articles in the media than Glaukos. MarketBeat recorded 13 mentions for DexCom and 4 mentions for Glaukos. Glaukos' average media sentiment score of 1.67 beat DexCom's score of 1.19 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
DexCom	7 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos presently has a consensus target price of $178.08, indicating a potential downside of 0.07%. DexCom has a consensus target price of $88.71, indicating a potential upside of 0.92%. Given DexCom's stronger consensus rating and higher probable upside, analysts clearly believe DexCom is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

DexCom has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	20.71	-$187.69M	-$3.25	N/A
DexCom	$4.66B	7.11	$836.30M	$2.53	34.74

Glaukos has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, DexCom has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

DexCom beats Glaukos on 13 of the 17 factors compared between the two stocks.

How does Glaukos compare to GE HealthCare Technologies?

Glaukos (NYSE:GKOS) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

GE HealthCare Technologies has a net margin of 9.33% compared to Glaukos' net margin of -30.68%. GE HealthCare Technologies' return on equity of 20.12% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
GE HealthCare Technologies	9.33%	20.12%	5.74%

In the previous week, GE HealthCare Technologies had 7 more articles in the media than Glaukos. MarketBeat recorded 11 mentions for GE HealthCare Technologies and 4 mentions for Glaukos. Glaukos' average media sentiment score of 1.67 beat GE HealthCare Technologies' score of 1.17 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
GE HealthCare Technologies	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

GE HealthCare Technologies has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	20.71	-$187.69M	-$3.25	N/A
GE HealthCare Technologies	$20.63B	1.51	$2.08B	$4.36	15.79

Glaukos currently has a consensus price target of $178.08, suggesting a potential downside of 0.07%. GE HealthCare Technologies has a consensus price target of $77.73, suggesting a potential upside of 12.88%. Given GE HealthCare Technologies' higher possible upside, analysts clearly believe GE HealthCare Technologies is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
GE HealthCare Technologies	0 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.48

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are owned by institutional investors. 5.9% of Glaukos shares are owned by company insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

GE HealthCare Technologies beats Glaukos on 9 of the 16 factors compared between the two stocks.

How does Glaukos compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Glaukos (NYSE:GKOS) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Koninklijke Philips has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Glaukos has a consensus price target of $178.08, suggesting a potential downside of 0.07%. Given Glaukos' stronger consensus rating and higher possible upside, analysts plainly believe Glaukos is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$20.17B	1.26	$1.01B	$1.36	19.04
Glaukos	$507.44M	20.71	-$187.69M	-$3.25	N/A

13.7% of Koninklijke Philips shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 5.9% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Glaukos had 1 more articles in the media than Koninklijke Philips. MarketBeat recorded 4 mentions for Glaukos and 3 mentions for Koninklijke Philips. Glaukos' average media sentiment score of 1.67 beat Koninklijke Philips' score of 0.52 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Koninklijke Philips has a net margin of 6.30% compared to Glaukos' net margin of -30.68%. Koninklijke Philips' return on equity of 14.38% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	6.30%	14.38%	5.96%
Glaukos	-30.68%	-6.37%	-4.78%

Summary

Glaukos beats Koninklijke Philips on 8 of the 15 factors compared between the two stocks.

How does Glaukos compare to STERIS?

Glaukos (NYSE:GKOS) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 5.9% of Glaukos shares are owned by company insiders. Comparatively, 1.1% of STERIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Glaukos and Glaukos both had 4 articles in the media. Glaukos' average media sentiment score of 1.67 beat STERIS's score of 0.99 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
STERIS	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos currently has a consensus target price of $178.08, suggesting a potential downside of 0.07%. STERIS has a consensus target price of $271.33, suggesting a potential upside of 20.81%. Given STERIS's higher possible upside, analysts clearly believe STERIS is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

STERIS has a net margin of 13.34% compared to Glaukos' net margin of -30.68%. STERIS's return on equity of 14.34% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
STERIS	13.34%	14.34%	9.66%

STERIS has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	20.71	-$187.69M	-$3.25	N/A
STERIS	$5.94B	3.69	$782.30M	$8.18	27.46

Glaukos has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, STERIS has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Summary

STERIS beats Glaukos on 9 of the 15 factors compared between the two stocks.

Get Glaukos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GKOS vs. The Competition

Export

Metric	Glaukos	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$10.51B	$5.66B	$7.21B	$23.59B
Dividend Yield	N/A	1.76%	2.54%	3.73%
P/E Ratio	-54.83	25.99	273.82	29.33
Price / Sales	20.71	72.77	628.18	19.82
Price / Cash	N/A	33.42	28.92	19.95
Price / Book	15.60	6.10	10.92	4.83
Net Income	-$187.69M	$150.94M	$3.49B	$1.07B
7 Day Performance	-0.70%	-1.06%	1.63%	0.43%
1 Month Performance	-1.13%	1.02%	4.42%	-0.78%
1 Year Performance	90.12%	9.88%	24.20%	12.82%

Glaukos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GKOS Glaukos	1.5126 of 5 stars	$178.20 +0.4%	$178.08 -0.1%	+90.1%	$10.51B	$507.44M	N/A	1,094	Positive News
RMD ResMed	4.2753 of 5 stars	$240.03 -0.1%	$240.31 +0.1%	-17.6%	$34.67B	$5.65B	23.01	11,370	Positive News Insider Trade
DXCM DexCom	4.174 of 5 stars	$91.06 +0.3%	$88.71 -2.6%	+9.2%	$34.27B	$4.66B	35.99	11,000	Positive News Analyst Upgrade
GEHC GE HealthCare Technologies	4.3451 of 5 stars	$71.23 -0.7%	$77.73 +9.1%	-9.1%	$32.40B	$20.63B	16.34	54,000	Positive News
PHG Koninklijke Philips	3.014 of 5 stars	$26.63 -0.3%	N/A	-7.3%	$26.26B	$20.17B	19.62	65,340

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GKOS) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Glaukos (GKOS) Competitors